CLAIMS

What is claimed is:

1. A compound of formula I,



I

in which

A is (C_1-C_8)alkyl, (C_0-C_8)alkylenearyl; a 3- to 12-membered mono- or bicyclic ring which may contain one or more heteroatoms selected from the group consisting of N, O and S and the 3- to 12-membered ring may carry further substituents selected from the group consisting of F, Cl, Br, NO_2, CF_3, OCF_3, CN, (C_1-C_6)alkyl, aryl, CON(R37)(R38), N(R39)(R40), OH, O-(C_1-C_6)alkyl, S-(C_1-C_6)alkyl, and NHCO(C_1-C_6)alkyl;

X is a bond, C(R8)(R9), C(OR10)(R11), O, N(R12), S, SO, SO_2, or CO;

R8, R9, R10, R11, R12 are independently of one another H, or (C_1-C_6)alkyl;

D is N, or C(R41);

E is N, or C(R42);

G is N, or C(R43);

L is N, or C(R44);

R1, R2, R3, R41, R42, R43, R44 are independently of one another H, F, Cl, Br, J, OH, CF_3, NO_2, CN, OCF_3, O-(C_1-C_6)alkyl, (C_1-C_4)alkoxyalkyl, S-(C_1-C_6)alkyl, (C_1-C_6)alkyl, (C_2-C_6)alkenyl, (C_3-C_8)cycloalkyl, O-(C_3-C_8)cycloalkyl, (C_3-C_8)cycloalkenyl, O-(C_3-C_8)cycloalkenyl, (C_2-C_6)alkynyl, (C_0-C_8)alkylenearyl, -O-(C_0-C_8)alkylenearyl, S-aryl, N(R13)(R14), SO_2-CH_3, COOH, COO-(C_1-C_6)alkyl, CON(R15)(R16), N(R17)CO(R18), N(R19)SO_2(R20), CO(R21), or a 5- to 7-membered heterocycle having 1-4 heteroatoms;

R13, R14 are independently of one another H, (C_1-C_6)alkyl, or R13 and R14 together with the nitrogen atom to which they are bonded form a 5- to 6-membered ring, where, in the case of the 6-membered ring, a CH_2 group may be replaced by O or S;

R15, R16 are independently of one another H, (C_1-C_6)alkyl, or R15 and R16 together with the nitrogen atom to which they are bonded form a 5- to 6-membered ring, where, in the case of the 6-membered ring, a CH_2 group may be replaced by O or S;

R17, R19 are independently of one another H, or (C_1-C_6)alkyl;

R18, R20, R21 are independently of one another (C_1-C_6)alkyl, or aryl;

B is N(R24), or O;

R24 is H, or (C_1-C_6)alkyl;

R5 is H, or (C_1-C_6)alkyl;

W is N, or C(R25);

R25 is H, (C_1-C_6)alkyl, aryl, or a bond to Y;

T is N, or C(R26);

R26 is H, $(C_1$-$C_6)$alkyl, aryl, $(C_0$-$C_8)$alkylenearyl, or a bond to Y;

U is O, S, N(R27), -C(R30)=N-, or -N=C(R31)-;

R27, R30, R31 are independently of one another H, $(C_1$-$C_6)$alkyl, or a bond to Y;

Y is $(C_1$-$C_8)$alkylene, in which one or more carbons may be replaced by O, S, SO, SO_2, C(R32)(R33), CO, C(R34)(OR35) or N(R36);

R32, R33, R34, R35, R36 are independently of one another H, $(C_1$-$C_6)$alkyl, or aryl;

R6, R7 are independently of one another H, $(C_1$-$C_6)$alkyl, $(C_3$-$C_7)$cycloalkyl, or R6 and Y or R6 and R7 together with the nitrogen atom to which they are bonded form a 3- to 8-membered ring in which one or more carbons may be replaced by O, N or S and the 3- to 8-membered ring may carry further substituents such as $(C_1$-$C_6)$alkyl, aryl, CON(R37)(R38), N(R39)(R40), OH, O-$(C_1$-$C_6)$alkyl or NHCO$(C_1$-$C_6)$alkyl;

R37, R38, R39, R40 are independently of one another H, or $(C_1$-$C_6)$alkyl;

and the physiologically acceptable salts thereof.

2. A compound of formula I as claimed in claim 1, wherein

A is $(C_2$-$C_7)$alkyl, $(C_0$-$C_3)$alkylenearyl; a 4- to 10-membered mono- or bicyclic ring which may contain one or more heteroatoms selected from the group consisting of N, O and S, and the 4- to 10-membered ring may carry further substituents selected from the group consisting of F, Cl, Br, NO_2, CF_3, $(C_1$-$C_6)$alkyl, aryl, CON(R37)(R38), N(R39)(R40), O-$(C_1$-$C_6)$alkyl, and NHCO$(C_1$-$C_6)$alkyl;

X is a bond, C(R8)(R9), O, N(R12), S, or SO_2;

R8, R9, R12 are independently of one another H, or $(C_1$-$C_6)$alkyl;

D is N, or C(R41);

E is N, or C(R42);

G is N, or C(R43);

L is N, or C(R44);

where the total number of the nitrogen atoms defined by D, E, G and L is 0, 1 or 2;

R1, R2, R3, R41, R42, R43, R44 are independently of one another H, F, Cl, Br, CF_3, NO_2, O-$(C_1$-$C_6)$alkyl, $(C_1$-$C_6)$alkyl, $(C_3$-$C_8)$cycloalkyl, O-$(C_3$-$C_8)$cycloalkyl, $(C_2$-$C_6)$alkynyl, $(C_0$-$C_8)$alkylenearyl, -O-$(C_0$-$C_3)$alkylenearyl, S-aryl, N(R13)(R14), SO_2-CH_3, COO-$(C_1$-$C_6)$alkyl, CON(R15)(R16), N(R17)CO(R18), N(R19)SO_2(R20), or CO(R21);

R13, R14 are independently of one another H, $(C_1$-$C_6)$alkyl, or R13 and R14 together with the nitrogen atom to which they are bonded form a 5- to 6-membered ring, where, in the case of the 6-membered ring, a CH_2 group may be replaced by O or S;

R15, R16 are independently of one another H, $(C_1$-$C_6)$alkyl, or R15 and R16 together with the nitrogen atom to which they are bonded form a 5- to 6-membered ring, where, in the case of the 6-membered ring, a CH_2 group may be replaced by O or S;

R17, R19 are independently of one another H, or $(C_1$-$C_6)$alkyl;

R18, R20, R21 are independently of one another (C_1-C_6)alkyl, or aryl;

B is N(R24), or O;

R24 is H, or (C_1-C_6)alkyl;

R5 is H, or (C_1-C_6)alkyl;

W is N, or C(R25);

R25 is H, (C_1-C_6)alkyl, or aryl;

T is C(R26);

R26 is H, (C_1-C_6)alkyl, aryl, or a bond to Y;

U is O, S, N(R27), or -N=C(R31)-;

R27, R31 are independently of one another H, (C_1-C_6)alkyl, or a bond to Y;

Y is (C_1-C_4)alkylene, in which a carbon may be replaced by SO_2, C(R32)(R33), CO or N(R36);

R32, R33, R36 are independently of one another H, (C_1-C_6)alkyl, or aryl;

R6, R7 are independently of one another H, (C_1-C_6)alkyl, (C_3-C_7)cycloalkyl, or R6 and Y or R6 and R7 together with the nitrogen atom to which they are bonded form a 4- to 7-membered ring in which one or more carbons may be replaced by O, N or S and the 4- to 7-membered ring may carry further substituents selected from the group consisting of (C_1-C_6)alkyl, aryl, CON(R37)(R38), N(R39)(R40), OH and NHCO(C_1-C_6)alkyl;

R37, R38, R39, R40 are independently of one another H, or (C_1-C_6)alkyl;

and the physiologically acceptable salts thereof.

3. A compound of formula I as claimed in either of claims 1 and 2, wherein

A is (C_3-C_7)alkyl, (C_0-C_2)alkylenearyl; a 5- to 10-membered mono- or bicyclic ring which may contain 0, 1 or 2 heteroatoms selected from the group consisting of N, O and S, and the 5- to 10-membered ring may carry further substituents selected from the group consisting of F, Cl, Br, NO_2, CF_3, (C_1-C_6)alkyl, aryl, O-(C_1-C_6)alkyl and NHCO(C_1-C_6)alkyl;

X is a bond, C(R8)(R9), O, or N(R12);

R8, R9, R12 are independently of one another H, or (C_1-C_6)alkyl;

D is N, or C(R41);

E is N, or C(R42);

G is N, or C(R43);

L is N, or C(R44);

where the total number of the nitrogen atoms defined by D, E, G and L is 0 or 1;

R1, R2, R3, R41, R42, R43, R44 are independently of one another H, F, Cl, CF_3, NO_2, O-(C_1-C_6)alkyl, (C_1-C_6)alkyl, O-(C_3-C_8)cycloalkyl, (C_0-C_2)alkylenearyl, -O-(C_0-C_3)alkylenearyl, N(R13)(R14), COO-(C_1-C_6)alkyl, CON(R15)(R16), N(R17)CO(R18), N(R19)SO_2(R20), or CO(R21);

R13, R14 are independently of one another H, or (C_1-C_6)alkyl,

R15, R16 are independently of one another H, or (C_1-C_6)alkyl,

R17, R19 are independently of one another H, or (C_1-C_6)alkyl;

R18, R20, R21 are independently of one another (C_1-C_6)alkyl, or aryl;

B is N(R24);

R24 is H, or (C_1-C_6)alkyl;

R5 is H, or (C_1-C_6)alkyl;

W is N, or C(R25);

R25 is H, or (C_1-C_6)alkyl;

T is C(R26);

R26 is H, (C_1-C_6)alkyl, or a bond to Y;

U is O, S, or N(R27);

R27 is H, (C_1-C_6)alkyl, or a bond to Y;

Y is (C_1-C_3)alkylene, in which a carbon may be replaced by SO_2, C(R32)(R33) or CO;

R32, R33 are independently of one another H, (C_1-C_6)alkyl, or aryl;

R6, R7 are independently of one another H, (C_1-C_6)alkyl, (C_3-C_7)cycloalkyl, or R6 and Y or R6 and R7 together with the nitrogen atom to which

they are bonded form a 5- or 6-membered ring in which one or more carbons may be replaced by O or N and the 5- or 6-membered ring may carry further substituents selected from the group consisting of $(C_1\text{-}C_6)$alkyl, aryl, CON(R37)(R38), N(R39)(R40), OH and NHCO$(C_1\text{-}C_6)$alkyl;

R37, R38, R39, R40 are independently of one another H, or $(C_1\text{-}C_6)$alkyl;

and the physiologically acceptable salts thereof.

4. A pharmaceutical composition comprising one or more of the compounds as claimed in claim 1 and a physiologically acceptable carrier.

5. A pharmaceutical composition comprising one or more of the compounds as claimed in claim 1, one or more anorectic active substances and a physiologically acceptable carrier.

6. A method for the prophylaxis or treatment of obesity comprising administering to a mammal in need thereof an effective amount of a compound as claimed in claim 1, or a physiologically acceptable salt thereof.

7. A method for the prophylaxis or treatment of type II diabetes comprising administering to a mammal in need thereof an effective amount of a compound as claimed in claim 1, or a physiologically acceptable salt thereof.

8. The method of claim 6, further comprising administering an effective amount of an anorective active substance.

9. The method of claim 7, further comprising administering an effective amount of an anorective active substance.

10. A method for preparing a pharmaceutical comprising one or more of the compounds as claimed claim 1, which comprises mixing the active substance

with a pharmaceutically suitable carrier and bringing said mixture into a form suitable for administration.

11. A method for the prophylaxis or treatment of arterioscerosis or high blood pressure comprising administering to a mammal in need thereof an effective amount of a compound as claimed in claim 1, or a physiologically acceptable salt thereof.

12. A method for normalizing lipid metabolism comprising administering to a mammal in need thereof an effective amount of a compound as claimed in claim 1, or a physiologically acceptable salt thereof.

13. A method for the prophylaxis or treatment of paresthesia, depression, anxiety, anxiety neuroses, or schizophrenia comprising administering to a mammal in need thereof an effective amount of a compound as claimed in claim 1, or a physiologically acceptable salt thereof.

14. A method for the prophylaxis or treatment of disorders associated with the circadian rhythm comprising administering to a mammal in need thereof an effective amount of a compound as claimed in claim 1, or a physiologically acceptable salt thereof.

15. A method for the treatment of drug abuse comprising administering to a mammal in need thereof an effective amount of a compound as claimed in claim 1, or a physiologically acceptable salt thereof.